Global Mavacamten Market Strategic Research Report

Scope of the Report

The global Mavacamten market size is predicted to grow from US$ 937 million in 2025 to US$ 7,408 million in 2032; it is expected to grow at a CAGR of 19.5% from 2026 to 2032.

Mavacamten is an oral, selective, allosteric inhibitor of cardiac myosin, designed to treat obstructive hypertrophic cardiomyopathy (HCM) by reducing excessive myocardial contractility and improving left ventricular outflow tract obstruction. It modulates actin-myosin cross-bridge formation in a reversible manner, thereby alleviating symptoms such as dyspnea, fatigue, and chest pain while enhancing exercise capacity in patients with symptomatic HCM. As a first-in-class targeted therapy, mavacamten offers a novel pharmacological approach beyond conventional beta-blockers and calcium channel blockers, demonstrating favorable efficacy and safety profiles in clinical trials and becoming an important treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy.In 2025, global Mavacamten production reached approximately 12 million units.

As the first-in-class cardiac myosin inhibitor approved globally, mavacamten has established a core position in the treatment of obstructive hypertrophic cardiomyopathy (oHCM), a rare disease with a long-standing high unmet medical need, owing to its pioneering nature and well‑defined clinical efficacy. Its launch has completely transformed the traditional treatment paradigm, which relied on beta‑blockers, calcium channel blockers, and surgical interventions. By precisely targeting the underlying pathogenesis of the disease, mavacamten significantly improves cardiac function and quality of life in patients. On the global market, the drug has rapidly built brand barriers and established market dominance through its first‑mover advantage and robust physician education programs. In the Chinese market, its successful inclusion in medical insurance has greatly improved accessibility, making it a key driver of the drug’s global growth. Competition in the market is becoming increasingly fierce, with new drugs of the same mechanism entering the market one after another and exerting diversion pressure through differentiated advantages such as convenient administration. This has prompted mavacamten to consolidate its leading position by continuously expanding its indications, accumulating long‑term real‑world data, and optimizing treatment regimens. Overall, the targeted therapy market for hypertrophic cardiomyopathy, in which mavacamten operates, is undergoing rapid expansion. The industry focus is shifting from conventional symptom management to precise etiological treatment, and the market will continue to evolve driven by multiple factors including indication expansion, increased market penetration, and optimization of the competitive landscape.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Mavacamten market?

What factors are driving Mavacamten market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Mavacamten market opportunities vary by end market size?

How does Mavacamten break out by Type, by Application?

This report presents a comprehensive overview of the global Mavacamten market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 2.5 mg
• 5 mg

Segment by Combination Therapy

• Combination with Beta-Blockers
• Combination with Calcium Channel Blockers

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Treatment Of Obstructive Hypertrophic Cardiomyopathy
• Improvement Of Cardiac Function
• Relief Of Symptoms Such As Dyspnea And Fatigue
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mavacamten market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Treatment Of Obstructive Hypertrophic Cardiomyopathy, Improvement Of Cardiac Function, Relief Of Symptoms Such As Dyspnea And Fatigue evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact